AbbVie is a global, research-based biopharmaceutical company. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
Company Growth (employees)
North Chicago, US
Size (employees)
30,000 (est)
AbbVie was founded in 2013 and is headquartered in North Chicago, US

Key People/Management at AbbVie

Richard Gonzalez

Richard Gonzalez

Chairman of the Board and Chief Executive Officer
Laura Schumacher

Laura Schumacher

Executive Vice President, External Affairs, General Counsel and Corporate Secretary
William Chase

William Chase

Executive Vice President and Chief Financial Officer
Carlos Alban

Carlos Alban

Executive Vice President, Commercial Operations
Michael Severino

Michael Severino

Executive Vice President, Research & Development and Chief Scientific Officer
Henry Gosebruch

Henry Gosebruch

Executive Vice President and Chief Strategy Officer
Timothy Richmond

Timothy Richmond

Senior Vice President, Human Resources​
Azita Saleki-Gerhardt

Azita Saleki-Gerhardt

Senior Vice President, Operations
Karen Hale

Karen Hale

Vice President, Chief Ethics and Compliance Officer
Wulff-Erik Von Borcke

Wulff-Erik Von Borcke

President, Pharmacyclics

AbbVie Office Locations

AbbVie has an office in North Chicago
North Chicago, US (HQ)
1 Waukegan Rd
Show all (1)

AbbVie Financials and Metrics

AbbVie Financials

AbbVie's revenue was reported to be $25.6 b in FY, 2016

Revenue (Q2, 2017)

6.9 b

Gross profit (Q2, 2017)

5.4 b

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

1.9 b

EBIT (Q2, 2017)

2.7 b

Market capitalization (23-Feb-2018)

190.4 b

Cash (30-Jun-2017)

6.1 b


184.7 b
AbbVie's current market capitalization is $190.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


18.8 b20 b22.9 b25.6 b

Revenue growth, %


Cost of goods sold

4.6 b4.4 b4.5 b5.8 b

Gross profit

14.2 b15.5 b18.4 b19.8 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


4.7 b4.6 b4.9 b5 b5 b5.5 b5.9 b6 b6.5 b6.4 b6.5 q6.9 b

Cost of goods sold

1.1 b1.1 b1.1 b1.1 b942 m916 m1.2 b1.4 b1.4 b1.5 b1.6 q1.5 b

Gross profit

3.6 b3.5 b3.8 b3.9 b4.1 b4.6 b4.8 b4.6 b5 b4.9 b4.9 q5.4 b

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


9.6 b8.3 b8.4 b5.1 b

Accounts Receivable

3.9 b3.7 b4.7 b4.8 b


1.2 b1.1 b1.7 b1.4 b

Current Assets

17.8 b16.1 b16.3 b16.2 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


9 b8.1 b9.1 b7.7 b7.9 b7.4 b9.2 b7.6 b6.3 b6.2 b4.7 b6.1 b

Accounts Receivable

3.8 b3.7 b3.7 b3.6 b4.2 b4.4 b4.6 b4.8 b5 b5 b4.7 b4.9 b


1.2 b1.1 b1 b1 b1 b1.6 b1.8 b1.8 b1.8 b1.6 b1.4 b1.6 b

Current Assets

16.5 b17.3 b17.8 b17.6 b15.4 b16.9 b17.9 b16.6 b16.8 b16.3 b15.5 b17 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1 b1.8 b5.1 b6 b

Accounts Receivable

681 m(172 m)(1.1 b)(71 m)


(56 m)(203 m)(434 m)(38 m)

Accounts Payable

(426 m)(193 m)1.5 b(1.2 b)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

964 m980 m1.1 b2.6 b1 b2.4 b3.6 b1.4 b3 b4.6 b1.7 b3.6 b

Depreciation and Amortization

593 m158 m348 m575 m268 m557 m861 m374 m753 m

Accounts Receivable

81 m(194 m)(129 m)(34 m)(167 m)


20 m(75 m)(160 m)(446 m)19 m(160 m)28 m71 m1 m
USDY, 2017


69.1 x


231.5 k

Financial Leverage

11.1 x
Show all financial metrics

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRxApril 28, 2016$5.8 b

AbbVie Market Value History

AbbVie Median Salaries

Source: 442 public H-1B filings from AbbVie

AbbVie's Web-traffic and Trends

AbbVie Online and Social Media Presence

AbbVie News and Updates

Newer psoriasis drugs top the old, but it's not efficacy that counts. It's payer negotiations: analyst

With this weekend’s American Academy of Dermatology meeting officially wrapped up, one thing is clear: Psoriasis treatments are getting more effective. But that doesn’t mean patients have easy access to a new-and-improved crop of blockbuster hopefuls.

Gilead wins reversal of $2.54B hepatitis C patent verdict, but Merck says fight not over yet

The latest victory in a years-long hepatitis C patent battle between Gilead Sciences and Merck goes to Gilead. On Friday, a federal judge overturned a $2.54 billion verdict against the biotech on grounds that a key Merck patent used to support the infringement lawsuit is invalid.

Bi-Specific Antibodies Market 2018 Global Analysis,Research,Review,Applications and Forecast to 2022

WiseGuyReports.Com Publish a New Market Research Report On –“ Bi-Specific Antibodies Market 2018 Global Analysis,Research,Review,Applications and Forecast to 2022”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Pharmaceutical Contract Manufacturing & Contract Market Increasing Demand with Leading Key Players: AbbVie, Baxter BioPharma Solutions, Patheon, Grifols International

HTF MI published a new industry research that focuses on Pharmaceutical Contract Manufacturing & Contract market and delivers in-depth market analysis and future prospects of Global Pharmaceutical Contract Manufacturing & Contract market. The study covers significant data which makes the res…

Uveitis Treatment Market to Witness a Rise of US$ 822.5 million by 2020

Uveitis Treatment Market: Asia Market to Witness fastest Growth by 2020. Global Uveitis Treatment Market is expected to reach USD 822.5 million by 2020 Posted via Industry Today. Follow us on Twitter @IndustryToday

Who won and who lost in tax reform? AbbVie, of course, but Regeneron, Roche, AstraZeneca and more

The pharma industry on the whole is getting a boost from tax reform, but some will reap far more savings than others. And some will actually have to pay more. Here's our report card.
Show more

AbbVie Company Life and Culture

You may also be interested in